Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. METHODS: In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors. RESULTS: Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication. CONCLUSIONS: The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01927419.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“(% [95% CI])† 44 (61 [49–72]) 4 (11 [3–25]) 12 (52 [31–73]) 1 (10 [0–45])”
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Not reported 1 (1) 1 (3) 1 (1) 1 (2) 2 (1)”
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“>ULN 15 (21) 7 (19) 24 (25) 11 (23) 35 (25)”
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 3×
“Stable disease 9 (12) 13 (35) 3 (13) 1 (10)”
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“M1b 22 (31) 8 (22) 27 (28) 12 (26) 39 (27)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 4×
“Increased lipase 12 (13) 8 (9) 2 (4) 1 (2)”
InfluentialSelf-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citation
Cited by
Items 501–600 of 1,008
Combinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 105
Alva, A. S., Daniels, G. A., Wong, M. K., Kaufman, H. L., Morse, M. A., McDermott, D. F., Clark, J. I., Agarwala, S. S., Miletello, G. P., Logan, T. F., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1910-x · Cited by 115
Self-citationNeutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
Cassidy, M. R., Wolchok, R. E., Zheng, J., Panageas, K. S., Wolchok, J. D., Coit, D., Postow, M. A., & Ariyan, C. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.029 · Cited by 104
Self-citationCOX-2 expression positively correlates with PD-L1 expression in human melanoma cells
Botti, G., Fratangelo, F., Cerrone, M., Liguori, G., Cantile, M., Anniciello, A. M., Scala, S., D’Alterio, C., Trimarco, C., Ianaro, A., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1150-7 · Cited by 104
Donia, M., Kimper-Karl, M. L., Høyer, K. L., Bastholt, L., Schmidt, H., & Svane, I. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.017 · Cited by 105
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 121
Yang, S., Liu, T., Nan, H., Wang, Y., Chen, H., Zhang, X., Zhang, Y., Shen, B., Qian, P.-D., Xu, S., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29018 · Cited by 116
“Despite advanced therapeutic methods, such as chemotherapies and radiotherapies, targeted therapies and immunotherapies, persistent limitations include low durable response, development of drug tolerance, toxicity, and high cost (Pelster & Amaria, 2019; Postow et al., 2015; Shah & Dronca, 2014).”
BackgroundMcKay, R. R., McGregor, B. A., Xie, W., Braun, D. A., Wei, X. X., Kyriakopoulos, C. E., Zakharia, Y., Maughan, B. L., Rose, T. L., Stadler, W. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02295 · Cited by 113
“At the time our study was designed, data in melanoma demonstrated that approximately 40% of patients treated with ipilimumab were not able to receive all four intended doses.(16) Additionally, CheckMate-016 investigating differing dosing regimens of nivolumab and ipilimumab in RCC demonstrated differences in toxicity…”
Self-citationmRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalikhani-hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 104
“Combination therapy with ipilimumab and nivolumab was also approved in 2015 for the treatment of stage III and IV melanoma patients [7].”
MethodImmune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
van der Vlist, M., Kuball, J. H. E., Radstake, T. R. D. J., & Meyaard, L. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.131 · Cited by 118
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies
Park, J. A., & Cheung, N.-K. V. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.006 · Cited by 103
Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.014 · Cited by 103
New insight in endocrine-related adverse events associated to immune checkpoint blockade
Elia, G., Ferrari, S. M., Galdiero, M. R., Ragusa, F., Paparo, S. R., Ruffilli, I., Varricchi, G., Fallahi, P., & Antonelli, A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101370 · Cited by 113
“Building upon the remarkable activity seen in patients with melanoma, several studies are exploring various combinations of different ICIs (57,58).”
BackgroundHuang, L., Malu, S., McKenzie, J. A., Andrews, M. C., Talukder, A. H., Tieu, T., Karpinets, T., Haymaker, C., Forget, M.-A., Williams, L. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2483 · Cited by 102
A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Zanetti, M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.67 · Cited by 109
Tomioka, N., Azuma, M., Ikarashi, M., YAMAMOTO, M., Sato, M., Watanabe, K., Yamashiro, K., & Takahashi, M. (2017) · Breast Cancer · doi:10.1007/s12282-017-0781-0 · Cited by 110
Kobold, S., Pantelyushin, S., Rataj, F., & Berg, J. V. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00285 · Cited by 108
Adoptive T cell therapy: An overview of obstacles and opportunities
Baruch, E. N., Berg, A. L., Besser, M. J., Schachter, J., & Markel, G. (2017) · Cancer · doi:10.1002/cncr.30491 · Cited by 118
Hao, C., Tian, J., Liu, H., Li, F., Niu, H., & Zhu, B. (2017) · Medicine · doi:10.1097/md.0000000000007325 · Cited by 113
Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 105
The use of combinations of monoclonal antibodies in clinical oncology
Henricks, L. M., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.10.008 · Cited by 117
Yun, S., Vincelette, N. D., Green, M. R., Hendrickson, A. E. W., & Abraham, I. L. (2016) · Cancer Medicine · doi:10.1002/cam4.732 · Cited by 103
Bilen, M. A., Subudhi, S. K., Gao, J., Tannir, N. M., Tu, S., & Sharma, P. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0139-8 · Cited by 101
Renal complications of immune checkpoint blockade
Murakami, N., Motwani, S. S., & Riella, L. V. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.004 · Cited by 104
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Young, A., Ngiow, S. F., Madore, J., Reinhardt, J., Landsberg, J., Chitsazan, A., Rautela, J., Bald, T., Barkauskas, D. S., Ahern, E. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0393 · Cited by 104
Kong, Y., Sheng, X., Wu, X., Yan, J., Ma, M., Yu, J., Si, L., Chi, Z., Cui, C., Dai, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0070 · Cited by 100
Immune checkpoint inhibitors for metastatic bladder cancer
Massari, F., Nunno, V. D., Cubelli, M., Santoni, M., Fiorentino, M., Montironi, R., Cheng, L., López-Beltrán, A., Battelli, N., & Ardizzoni, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.007 · Cited by 107
Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy
Sun, X., Zhang, N., Yin, C., Zhu, B., & Li, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00951 · Cited by 124
“and anti-PD-1 (86, 87) (NCT01927419) II Active, not recruiting Unresectable, previously”
BackgroundChmura, S. J., Winter, K. A., Robinson, C. G., Pisansky, T. M., Borges, V. F., Al‐Hallaq, H., Matuszak, M. M., Park, S. S., Yi, S., Hasan, Y., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0687 · Cited by 101
Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy
Escriche‐Navarro, B., Escudero, A. C., Lucena‐Sánchez, E., Sancenón, F., García‐Fernández, A., & Martínez‐Máñez, R. (2022) · Advanced Science · doi:10.1002/advs.202200756 · Cited by 101
Chesney, J. A., Puzanov, I. J., Collichio, F. A., Singh, P. P., Milhem, M. M., Glaspy, J. A., Hamid, O., Ross, M. I., Friedlander, P. A., Garbe, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006270 · Cited by 103
Self-citationImmune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets
Stahl, M. F., & Goldberg, A. D. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0781-7 · Cited by 109
The development of immunotherapy in older adults: New treatments, new toxicities?
Hélissey, C., Vicier, C., & Champiat, S. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.05.007 · Cited by 104
Aboudaram, A., Modesto, A., Chaltiel, L., Gomez‐Roca, C., Boulinguez, S., Sibaud, V., Delord, J., Chira, C., Delannes, M., Moyal, E. C., et al. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000386 · Cited by 98
Self-citationKehl, K. L., Yang, S., Awad, M. M., Palmer, N., Kohane, I. S., & Schrag, D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02321-z · Cited by 104
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance
Geraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., Funck-Brentano, E., Moslehi, J. J., Johnson, D. B., & Salem, J.-E. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022820-093805 · Cited by 96
Zheng, Z., Wieder, T., Mauerer, B., Schäfer, L., Kesselring, R., & Braumüller, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411673 · Cited by 133
“(ii) Nivolumab, an antibody that binds PD-1, for melanoma treatment [192].”
BackgroundLiu, J., Blake, S. J., Harjunpää, H., Fairfax, K. A., Yong, M. C. R., Allen, S., Kohrt, H. E., Takeda, K., Smyth, M. J., & Teng, M. W. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0194 · Cited by 97
Reuss, J. E., Kunk, P. R., Stowman, A. M., Gru, A. A., Slingluff, C. L., & Gaughan, E. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0199-9 · Cited by 97
Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
Rozeman, E. A., Dekker, T. J. A., Haanen, J. B. A. G., & Blank, C. U. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0325-6 · Cited by 109
Josefsson, S. E., Huse, K., Kolstad, A., Beiske, K., Pende, D., Steen, C. B., Inderberg, E. M., Lingjærde, O. C., Østenstad, B., Smeland, E. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2337 · Cited by 97
Imaging of T-cells and their responses during anti-cancer immunotherapy
Krekorian, M., Fruhwirth, G. O., Srinivas, M., Figdor, C. G., Heskamp, S., Witney, T. H., & Aarntzen, E. H. J. G. (2019) · Theranostics · doi:10.7150/thno.37924 · Cited by 106
“melanoma [1-3], non-small cell lung cancer [4, 5] and renal cell carcinoma [6].”
BackgroundHu, Y., Gong, J., Zhang, L., Li, X., Li, X., Zhao, B., & Hai, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106601 · Cited by 101
Metabolic regulation of immune responses: therapeutic opportunities
Assmann, N., & Finlay, D. K. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83005 · Cited by 97
Health-related quality of life results from the phase III CheckMate 067 study
Schadendorf, D., Larkin, J., Wolchok, J. D., Hodi, F. S., Chiarion‐Sileni, V., Gonzalez, R. C., Rutkowski, P. L., Grob, J., Cowey, C. L., Lao, C. D., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.031 · Cited by 105
Self-citationAutoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin
Jain, V., Mohebtash, M., Rodrigo, M. E., Ruiz, G., Atkins, M. B., & Barac, A. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000239 · Cited by 96
Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
Johnson, D. B., Pectasides, E., Feld, E., Ye, F., Zhao, S., Johnpulle, R. A. N., Merritt, R. M., McDermott, D. F., Puzanov, I. J., Lawrence, D. P., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000148 · Cited by 105
Self-citationImmunotherapy of cancers comes of age
Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 107
Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update
Kudo, M. (2017) · Oncology · doi:10.1159/000481245 · Cited by 103
Adam, J., Louvet, E., Sourisseau, T., Dorvault, N., Bernard, M., Maingot, E., Faivre, L., Cassin-Kuo, M.-S., Boissier, E., Dessoliers, M.-C., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000257 · Cited by 96
Identifying and managing the adverse effects of immune checkpoint blockade
Winer, A., Bodor, J. N., & Borghaei, H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.111 · Cited by 98
STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity
Falahat, R., Perez-Villarroel, P., Mailloux, A. W., Zhu, G., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0229 · Cited by 95
“Discussion Immunotherapies, including adoptive cell transfer of tumorinfiltrating lymphocytes and immune-checkpoint inhibitor antibodies, have shown efficacy in patients with metastatic melanoma (5, 20, 27).”
BackgroundReal World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
Asher, N., Ben‐Betzalel, G., Ari, S. L., Shapira‐Frommer, R., Steinberg‐Silman, Y., Gochman, N., Schachter, J., Meirson, T., & Markel, G. (2020) · Cancers · doi:10.3390/cancers12082329 · Cited by 97
Medler, T. R., Cotechini, T., & Coussens, L. M. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.07.008 · Cited by 109
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy
Ghasemzadeh, A., Bivalacqua, T. J., Hahn, N. M., & Drake, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1135 · Cited by 104
Approaches to modernize the combination drug development paradigm
Day, D., & Siu, L. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0369-x · Cited by 104
Wu, J., Hong, D., Zhang, X., Lu, X., & Miao, J. (2017) · Scientific Reports · doi:10.1038/srep44173 · Cited by 111
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 101
Wu, J., Zhang, H., Shi, X., Xiao, X., Fan, Y., Minze, L. J., Wang, J., Ghobrial, R. M., Xia, J., Sciammas, R., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.003 · Cited by 92
CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols
Seo, J. W., Tavaré, R., Mahakian, L. M., Silvestrini, M. T., Tam, S. M., Ingham, E. S., Salazar, F. B., Borowsky, A. D., Wu, A. M., & Ferrara, K. W. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0261 · Cited by 101
Ito, K., Schöder, H. M., Teng, R. S. Y., Humm, J. L., Ni, A., Wolchok, J. D., & Weber, W. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4211-0 · Cited by 98
Self-citationLeveraging Transcriptional Dynamics to Improve BRAF Inhibitor Responses in Melanoma
Smalley, I., Kim, E., Li, J., Spence, P., Wyatt, C. J., Eroglu, Z., Sondak, V. K., Messina, J. L., Babacan, N. A., Maria–Engler, S. S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.023 · Cited by 99
“hile this is usually undertaken with the hope of a curative esponse, only ~30% of patients are likely to respond [11,12].”
BackgroundImmune checkpoint inhibitors to treat cutaneous malignancies
M.S, D. M. B., Do, M. H., Phillips, G. S., Postow, M. A., Akaike, T., Nghiem, P., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.131 · Cited by 104
Self-citationArthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response
Smith, M. H., & Bass, A. R. (2019) · Arthritis Care & Research · doi:10.1002/acr.23467 · Cited by 92
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
Luo, N., Formisano, L., Gonzalez-Ericsson, P. I., Sanchez, V., Dean, P. T., Opalenik, S. R., Sanders, M. E., Cook, R. S., Arteaga, C. L., Johnson, D. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438106 · Cited by 87
Jennings, J. J., Mandaliya, R. H., Nakshabandi, A., & Lewis, J. H. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1574744 · Cited by 101
Ishihara, H., Takagi, T., Kondo, T., Homma, C., Tachibana, H., Fukuda, H., Yoshida, K., Iizuka, J., Kobayashi, H., Okumi, M., et al. (2019) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.03.003 · Cited by 92
Atkins, M. B., & Larkin, J. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv414 · Cited by 92
Rajan, A., Kim, C., Heery, C. R., Guha, U., & Gulley, J. L. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1175694 · Cited by 106
Personalized T cell-mediated cancer immunotherapy: progress and challenges
Bethune, M. T., & Joglekar, A. V. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.024 · Cited by 91
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 91
Gu, X., Wei, H., Suo, C., Shen, S., Zhu, C., Chen, L., Yan, K., Li, Z., Bian, Z., Zhang, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43988-4 · Cited by 106
PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
Zhang, J., Yan, Y., Li, J., Adhikari, R., & Fu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00722 · Cited by 101
“Combination therapy had an acceptable safety profile (Postow et al., 2015).”
BackgroundThe role of microbiota in cancer therapy
Perez-Chanona, E., & Trinchieri, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.01.003 · Cited by 90
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1
Jin, Z., & Yoon, H. H. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.06 · Cited by 93
Radiotherapy and immunotherapy: a synergistic effect in cancer care
Turgeon, G., Weickhardt, A. J., Azad, A., Solomon, B., & Siva, S. (2018) · The Medical Journal of Australia · doi:10.5694/mja2.12046 · Cited by 97
Chang, R. B., & Beatty, G. L. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir0320-475r · Cited by 106
Leong, A., & Kim, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228689 · Cited by 102
“In the case of melanoma, which is particularly susceptible to immunotherapies, approximately half of the patients treated with ICIs show resistance evidenced by disease progression after treatment [97,98].”
BackgroundKersten, K., Salvagno, C., & de Visser, K. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00516 · Cited by 89
Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0193 · Cited by 88
“With the FDA approval of immune-checkpoint blocking antibodies, initially targeting CTLA-4 in melanoma (1) and then for PD-1/PD-L1 in melanoma (2), non–small cell lung cancer (NSCLC; ref.”
BackgroundPD‐1 Pathway Inhibitors: Immuno‐Oncology Agents for Restoring Antitumor Immune Responses
Medina, P. J., & Adams, V. R. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1714 · Cited by 93
Adapting Cancer Immunotherapy Models for the Real World
Klevorn, L. E., & Teague, R. M. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.010 · Cited by 88
T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword
Simons, K. H., de Jong, A., Jukema, J. W., de Vries, M. R., Arens, R., & Quax, P. H. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0164-7 · Cited by 95
Huffaker, T. B., Lee, S.-H., Tang, W. W., Wallace, J. A., Alexander, M., Runtsch, M. C., Larsen, D. K., Thompson, J., Ramstead, A. G., Voth, W. P., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.808121 · Cited by 88
Immune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
Ahern, E., Harjunpää, H., Barkauskas, D., Allen, S., Takeda, K., Yagita, H., Wyld, D., Dougall, W. C., Teng, M. W. L., & Smyth, M. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0606 · Cited by 87
Immune reconstitution inflammatory syndrome in non‐ HIV immunosuppressed patients
Sueki, H., Mizukawa, Y., & Aoyama, Y. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.14074 · Cited by 94
Takeuchi, Y., Tanemura, A., Tada, Y., Katayama, I., Kumanogoh, A., & Nishikawa, H. (2018) · International Immunology · doi:10.1093/intimm/dxx073 · Cited by 86
Lopez, A. T., & Geskin, L. J. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0128 · Cited by 91
Li, T., Zhang, C., Zhao, G., Zhang, X., Hao, M., Hassan, S., Zhang, M., Zheng, H., Yang, D., Liu, L., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.036 · Cited by 93
The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer
McLachlan, J., Boussios, S., Okines, A. F. C., Glaessgen, D., Bodlar, S., Kalaitzaki, R., Taylor, A., Lalondrelle, S., Gore, M. E., Kaye, S. B., et al. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.10.002 · Cited by 85
Bukhari, S., Henick, B. S., WINCHESTER, R. J., Lerrer, S., Adam, K. R., Gartshteyn, Y., Maniar, R., Lin, Z., Khodadadi‐Jamayran, A., Tsirigos, A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100868 · Cited by 98
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer
Hu, Z. I., Ho, A. Y., & McArthur, H. L. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.029 · Cited by 90
Chang, X., Lu, X., Guo, J., & Teng, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.006 · Cited by 92
Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 99
Lipid-based nanosystems: the next generation of cancer immune therapy
Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 106
Abdel-Rahman, O., ElHalawani, H., & Fouad, M. (2015) · Immunotherapy · doi:10.2217/imt.15.87 · Cited by 85
Irradiation and immunotherapy: From concept to the clinic
Salama, A. K. S., Postow, M. A., & Salama, J. K. (2016) · Cancer · doi:10.1002/cncr.29889 · Cited by 85
Self-citationGeorge, S., Rini, B. I., & Hammers, H. J. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4604 · Cited by 84
Heppt, M. V., Eigentler, T., Kähler, K. C., Herbst, R. A., Göppner, D., Gambichler, T., Ulrich, J., Dippel, E., Loquai, C., Schell, B., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1856-z · Cited by 87
Metadata
- Authors
- Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D., Salama, A. K., Taylor, M., Ott, P. A., Rollin, L. M., Horak, C., Gagnier, P., Wolchok, J. D., & Hodi, F. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Université Paris-Sud (FR)
- Beth Israel Deaconess Medical Center (US)
- From Memorial Sloan Kettering Cancer Center (M.A.P., J.D.W.), Weill Cornell Medical College (M.A.P., J.D.W.), and New York University, Perlmutter Cancer Center (A.C.P.) — all in New York; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY (J.C.); Institute Gustave Roussy, Villejuif (C.R.), Paris-Sud University, Orsay (C.R.), and Institut Universitaire du Cancer, Toulouse (N.M.) — all in France; Huntsman Cancer Institute, Salt Lake City (K.G.); Beth Israel Deaconess Medical Center (D....
- Prisma Health (US)
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-21
- Volume
- 372
- Issue
- 21
- Pages
- 2006-2017
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5744258
- OpenAlex
- W2128758225
- Cited by
- 2,781
- References
- 28
- Citations by year
- 2026: 53 · 2025: 91 · 2024: 131 · 2023: 175 · 2022: 174 · 2021: 206 · 2020: 261 · 2019: 277 · 2018: 372 · 2017: 449 · 2016: 402 · 2015: 183
- FWCI
- 204.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, metastatic melanoma, combination immunotherapy, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, objective response rate, progression-free survival, BRAF V600 mutation, immune-related adverse events, first-line therapy, dose escalation, complete response, duration of response
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Disease-Free Survival, Tumor Burden, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.